A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
Status:
Completed
Trial end date:
2019-07-19
Target enrollment:
Participant gender:
Summary
This is a Phase 2, Open-label, Randomized, Multicenter Study to Investigate the Efficacy,
Safety, and Pharmacokinetics of Brivanib in Patients with Previously Treated Advanced
Hepatocellular Carcinoma.